What did @clshealth actually say?
Dr. Nicole Sheung laid out a simple split: Ozempic is "FDA approved for patients that have type 2 diabetes with additional benefit of weight loss," while Wegovy is "FDA approved for obesity" and used "in cooperation with diet and exercise." That's the whole video. Sixty seconds, two drugs, one distinction. Short, confident, and mostly accurate, but missing enough context that viewers could walk away with an incomplete picture of how these drugs actually work and who qualifies for them.
The framing suggests the decision is clean and binary. It isn't. Both drugs contain semaglutide. Both are manufactured by Novo Nordisk. The difference in FDA approval category matters legally and for insurance coverage, but clinically, the picture is considerably more complicated than this video lets on.
Does the science back this up?
On the core approvals, yes, the science backs her up. The FDA approved semaglutide 0.5 mg and 1 mg (Ozempic) for type 2 diabetes in December 2017, and later expanded approval to 2 mg. Wegovy, at a higher dose of 2.4 mg weekly, received FDA approval for chronic weight management in June 2021. These are real regulatory distinctions grounded in separate clinical trial programs.
The SUSTAIN trial series (Marso et al., 2016, New England Journal of Medicine) established Ozempic's cardiovascular and glycemic credentials in type 2 diabetes. The STEP trials (Wilding et al., 2021, New England Journal of Medicine) validated Wegovy's weight loss efficacy, showing roughly 15% average body weight reduction over 68 weeks. More recently, the SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) found Wegovy reduced major cardiovascular events by 20% in adults with obesity and established cardiovascular disease, which earned it an additional FDA indication in 2024. That 2024 cardiovascular indication for Wegovy is absent from this video entirely.
What did they get wrong (or right)?
She got the basic approval categories right. Credit where it's due. But calling Ozempic's weight loss an "additional benefit" undersells what is now a documented, trial-supported outcome. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) specifically enrolled people without diabetes and showed sustained weight loss over two years, reinforcing that semaglutide's weight effects aren't incidental.
The bigger gap is what she left out entirely. Wegovy now carries an FDA approval for reducing cardiovascular risk in adults with obesity or overweight who also have established heart disease. That's a significant clinical development that changes prescribing conversations. Additionally, the video implies Ozempic is not used for weight loss in practice. In reality, off-label prescribing of Ozempic for obesity is widespread, largely because Wegovy has faced persistent supply shortages. She doesn't mention that either. For 203,000 viewers trying to figure out which drug to ask their doctor about, that omission matters.
What should you actually know?
Both Ozempic and Wegovy contain semaglutide. The molecule is identical. The difference is the approved dose and the labeled indication, which affects how insurers cover each drug. Wegovy is dosed up to 2.4 mg weekly. Ozempic tops out at 2 mg. That dose difference is clinically meaningful for weight loss outcomes, not just a labeling technicality.
Insurance coverage often hinges on that FDA approval category. Many plans will cover Ozempic for a diabetes diagnosis but reject Wegovy claims for obesity alone. Some plans cover neither. The real-world prescribing conversation isn't just "which is right for you?" but also "which will your insurance actually pay for?" and "is it even in stock?"
If you have type 2 diabetes and obesity, you may qualify for either drug, and a physician should weigh your cardiovascular history, your insurance situation, and current availability. The SELECT trial data also means that patients with obesity and prior heart attacks or strokes now have a specific cardiovascular argument for Wegovy. That's worth knowing before your next doctor's appointment.
Bottom line
Dr. Sheung's core claims are accurate but stripped down to the point of being potentially misleading by omission. She's a credentialed endocrinologist and the approvals she cited are real. But a 60-second TikTok that ends with "now you know which one is right for you" implies a level of completeness this video doesn't deliver. The 2024 cardiovascular indication, the dose differences, the supply chain realities, and the off-label prescribing landscape all affect real patient decisions. Accurate isn't always the same as sufficient.